Last November, I compared Palo Alto Networks (NYSE:PANW) with FireEye (NASDAQ:FEYE) to see which one was the better play on the growing cybersecurity market. I concluded that FireEye was a slightly better pick than Palo Alto, due to its cost-cutting measures, lower valuation, and takeover potential.
Since that article was published, shares of Palo Alto have fallen 30%, while shares of FireEye....More>>>
Oil futures rose for a fourth straight session on Wednesday, trading at nearly 18-month highs on expectations the Organization of the Petroleum Exporting Countries and other major producing nations will make good on promises to cut output in the new year.
On the New York Mercantile Exchange, light, sweet crude futures for delivery in February ....More>>>
Welcome. In this article I will give the dollar and cents reasons for how come ERIC looks like a relative bargain in today’s marketplace.
In the trailing ten years ERIC has earned their market cap in free cash flow. This is a signal the company may be undervalued. If ERIC can repeat the performance and earn over $19B in the coming....More>>>
Any time a growth stock like Amazon (NSDQ:AMZN) comes under pressure, value investors come out in droves citing the company’s ridiculously high earnings multiple as reason enough to stay clear of the stock. Growth investors and value investors are two entirely different breeds. One looks for deeply discounted fundamentally strong companies whereas growth investors concentrate a lot on growth....More>>>
Facebook stock enters 2017 on a combination of lower expectations and depressed valuations. Flickr
Shares of Facebook (NSDQ:FB) are off to a great start in the new year. FB stock is up 8%+ since the turn of the year. In comparison, the stock had gained 9.55% in 2016, outperforming the Nasdaq Composite’s (INDX:COMPX) 6.6% gains. As reported in our last FB post, Facebook stock....More>>>
Amaya’s stock has been on a wild roller coaster ride this year, with catalysts ranging from the CEO (David Baazov) being accused of insider trading, to takeover rumors, to failed mergers and now a formal bid by the aforementioned CEO. There have certainly been a lot of hopes and headaches, but I believe there is a strong underlining long case to be made on Amaya. I wrote a blog post about....More>>>
There’s been a lot of talk that the revival of the Keystone XL pipeline–and the possibility of other pipelines as well–could boost the shares of steel makers like U.S. Steel (X), AK Steel (AKS), Nucor (NUE) and Steel Dynamics (STLD). Axiom Capital’s Gordon Johnson disagrees:
In a number of articles recently, following the US recent revival....More>>>
Accenture (NYSE:ACN) is a global technology consulting company that has been in the news a lot over the last month. On March 23, 2017, the company released its Q2 2017 results and revised full-year 2017 guidance, which were widely viewed as "disappointments" by the financial community. In Ap
Valeant Pharmaceuticals (NYSE:VRX) is by no means a healthy company. Investing in them is by no means for the faint of heart. Since hitting highs of $259.98 on August 4th, 2015, VRX has been a deathtrap for investors, losing 95% of its market value. There are many reasons for that decline, but I
Small cap RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) is focused on regenerative medicine - a game-changing area of medicine with the potential to fully heal damaged tissues and organs. According to Wikipedia, the term wasfirst used in a 1992 article on hospital administration by Leland Kaiser